[{"address1": "The Omeros Building", "address2": "201 Elliott Avenue West", "city": "Seattle", "state": "WA", "zip": "98119", "country": "United States", "phone": "206 676 5000", "website": "https://www.omeros.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.", "fullTimeEmployees": 198, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gregory A. Demopulos M.D.", "age": 64, "title": "Co-Founder, Chairman, CEO & President", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 5965279, "exercisedValue": 0, "unexercisedValue": 39325}, {"maxAge": 1, "name": "Mr. Peter B. Cancelmo J.D.", "age": 44, "title": "VP, General Counsel & Corporate Secretary", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 611435, "exercisedValue": 0, "unexercisedValue": 5500}, {"maxAge": 1, "name": "Dr. Pamela Pierce Palmer M.D., Ph.D.", "age": 60, "title": "Co-Founder", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David J. Borges", "age": 59, "title": "VP of Finance, Chief Accounting Officer & Treasurer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. George A. Gaitanaris M.D., Ph.D.", "age": 66, "title": "Chief Scientific Officer & VP of Science", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Peter W. Williams", "age": 55, "title": "Vice President of Human Resources", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Catherine A. Melfi Ph.D.", "age": 64, "title": "Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Nadia  Dac", "age": 53, "title": "VP & Chief Commercial Officer", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andreas  Grauer M.D.", "age": 62, "title": "VP & Chief Medical Officer", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 5, "overallRisk": 7, "governanceEpochDate": 1727481600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.92, "open": 3.97, "dayLow": 3.855, "dayHigh": 4.02, "regularMarketPreviousClose": 3.92, "regularMarketOpen": 3.97, "regularMarketDayLow": 3.855, "regularMarketDayHigh": 4.02, "beta": 1.482, "forwardPE": -1.6752138, "volume": 139417, "regularMarketVolume": 139417, "averageVolume": 325671, "averageVolume10days": 249790, "averageDailyVolume10Day": 249790, "bid": 3.88, "ask": 3.94, "bidSize": 100, "askSize": 300, "marketCap": 227151856, "fiftyTwoWeekLow": 0.92, "fiftyTwoWeekHigh": 5.68, "fiftyDayAverage": 4.2734, "twoHundredDayAverage": 3.83335, "currency": "USD", "enterpriseValue": 512595680, "floatShares": 55371121, "sharesOutstanding": 57946900, "sharesShort": 11842232, "sharesShortPriorMonth": 11687702, "sharesShortPreviousMonthDate": 1723680000, "dateShortInterest": 1726185600, "sharesPercentSharesOut": 0.2044, "heldPercentInsiders": 0.04445, "heldPercentInstitutions": 0.43313998, "shortRatio": 46.71, "shortPercentOfFloat": 0.2138, "bookValue": -2.15, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -199918000, "trailingEps": -3.32, "forwardEps": -2.34, "pegRatio": -0.02, "lastSplitFactor": "1:1", "lastSplitDate": 1254441600, "enterpriseToEbitda": -2.766, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "OMER", "underlyingSymbol": "OMER", "shortName": "Omeros Corporation", "longName": "Omeros Corporation", "firstTradeDateEpochUtc": 1255008600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3f7c487e-99e5-35b0-97bc-8da48930057f", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.92, "targetHighPrice": 43.0, "targetLowPrice": 43.0, "targetMeanPrice": 43.0, "targetMedianPrice": 43.0, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 158912000, "totalCashPerShare": 2.742, "ebitda": -185295008, "totalDebt": 444356000, "quickRatio": 2.808, "currentRatio": 3.412, "returnOnAssets": -0.26323998, "freeCashflow": -126165752, "operatingCashflow": -155236992, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-30"}]